Abstract: The present invention generally relates to novel protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavage site, wherein the linker has a length of 20 to 45 amino acids, wherein the masking moiety is covalently attached to the IL-2 polypeptide through the linker, wherein the masking moiety is capable of binding to the IL-2 polypeptide thereby reversibly concealing the IL-2 polypeptide, wherein the masking moiety comprises a second protease cleavage site, wherein the masking moiety does not conceal the IL-2 polypeptide upon cleavage at the first and/or the second protease cleavage site. The present invention also relates to polynucleotides encoding such protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates, and vectors and host cells comprising such polynucleotides.

Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: A computer-implemented method of identifying a tissue type in digital histological images of human or animal tissue comprises training a convolutional neural network (CNN) to identify a particular target tissue type in training data sets of digital histological images, inputting a test data set of digital histological images into the trained CNN, and receiving as an output result of the CNN a probability value that the inputted test data set corresponds to the target tissue type. A training procedure of the CNN comprises performing with training data sets: selecting a target tissue area of the training data set, dividing the target tissue area into different sets of tiles of constant size but having different image magnifications, and inputting the sets of tiles into a multi-headed CNN, wherein the sets of tiles having different image magnifications are processed in parallel and the features of the sets of tiles are concatenated.

Abstract: The invention relates to novel compounds having the general formula I, wherein Rx and Ry are as described herein, composition including the compounds and methods of using the compounds.

Abstract: Computer-implemented methods for predicting HPLC retention time for one or more compounds using machine learning models are disclosed. In particular, the use of machine learning models for identifying a set of HPLC method parameters suitable for separating two or more compounds in a composition is disclosed. Related systems and products are also described.

Abstract: Herein is reported a method for determining an anti-AAV particle antibody in a mammalian sample comprising the steps of diluting an aliquot of the sample, preferably to a final serum concentration between 5% (v/v) and 0.5% (v/v), adding AAV particles (AAVp) specifically bound by the anti-AAV particle antibody (AAV-ADA) to the diluted sample to generate a spiked sample, pre-incubating the spiked sample to allow the formation of a AAV-ADA-AAVp complex, and detecting the AAV-ADA-AAVp complex, thereby determining the anti-AAV antibody in the mammalian sample.

Abstract: The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.

Abstract: The present invention relates to a method for simulation of quality impact of transportation on a liquid, and a two-dimensional shaker adapted to perform said method.

Abstract: Systems and computer-implemented methods for tracking movement of a subject comprise and perform the steps of: Obtaining depth image data of a subject's body during a predefined time period and tracking locations of a plurality of anatomical landmarks of the body based on the depth image data. In addition, a location of a predefined point is tracked in an environment, in which the subject is moving. The location of the one or more of the plurality of anatomical landmarks is adjusted relative to the location of the predefined point to obtain adjusted locations. A movement of the subject's body is determined based on the adjusted locations during the predefined time period.

Abstract: Herein is reported a heterodimeric fusion polypeptide comprising a first proteinaceous moiety and a second proteinaceous moiety, wherein the first proteinaceous moiety and the second proteinaceous moiety are the first and the second antigen of a bispecific antibody which comprises a first binding site that specifically binds to the first proteinaceous moiety and a second binding site that specifically binds to the second proteinaceous moiety, wherein the first proteinaceous moiety is fused to the N-terminus of a first antibody heavy chain Fc-region polypeptide of the IgG1 subtype, wherein the second proteinaceous moiety is fused to the N-terminus of a second antibody heavy chain Fc-region polypeptide of the IgG1 subtype, wherein the first and the second heavy chain Fc-region polypeptide form a disulfide-linked heterodimer, wherein one or both of the heavy chain Fc-region polypeptides comprise a tag for immobilization to a solid phase at its C-terminus, and wherein the first and the second Fc-region polypeptid

Abstract: The present invention relates to pharmaceutical compositions comprising 5-ethyl-4-methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.

Abstract: The invention relates to pharmaceutical formulation in form of a pharmaceutical formulation comprising GDC-0077 (INAVOLISIB) or a salt thereof, the formulation having a colored coating.

Abstract: The present invention generally relates to bispecific antibodies that bind to CD3 and Folate Receptor 1 (FolR1), e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The invention relates to a process for the coupling of an aryl halogenide with an N-nucleophile compound which is characterized in that the coupling takes place in the presence of a dinuclear copper(II) complex bearing substituted salben-type ligands having the formula I Also described are novel dinuclear copper(II) complex bearing substituted salben-type ligands within the scope of formula I

Abstract: Provided herein are methods of synthesizing quinazoline compounds comprising at least one atropisomeric center.

Abstract: Herein is reported a method for co-cultivating B-cells in the presence of phorbol myristate acetate, IL-1beta, TNFalpha, IL-2, IL-10 and IL-6.

Abstract: Herein are provided a method for producing a multispecific antibody comprising the steps of providing a mammalian cell expressing the antibody, transfecting said mammalian cell with an expression vector comprising an expression cassette encoding a polypeptide of the antibody that has a domain crossover, cultivating the transfected cell and recovering the antibody from the cell or the cultivation medium and thereby producing the multispecific antibody.

Abstract: The present application discloses methods and uses for preparation of a dry solid composition as a precursor for a stable gel body formation upon addition of water. The invention also discloses the compositions obtained from said methods and uses. Said gel bodies can, for example, be used in pharmaceutical compositions to administer drug substances to patients with difficulties to swallow.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R5, T and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.